In the realm of biochemical research and synthetic biology, the study of specific protein fragments remains a cornerstone for understanding molecular interactions. Among the most frequently discussed subjects in laboratory literature is the OTII peptide sequence. My journey into analyzing these structures has provided a deep appreciation for the precision required in peptide synthesis and the specific functional roles these sequences play in controlled experimental environments.
The Foundation: OVA Peptide (323-339)
The primary focus for many researchers working with these models is the OVA Peptide (323-339). This specific segment, derived from the chicken ovalbumin protein, is a critical peptide sequence used extensively in research. With a molecular formula of C74H121N27O24 and a molecular weight of approximately 1772.9 Da, it is a well-characterized structure. Its sequence—Ile-Ser-Gln-Ala-Val-His-Ala-Ala-His-Ala-Glu-Ile-Asn-Glu-Ala-Gly-Arg (ISQAVHAAHAEINEAGR)—serves as a benchmark for studies involving antigen-specific interactions.
When discussing the OVA 323-339 peptide, it is essential to note that its utility stems from its role as an epitope. Ovalbumin protein Ova (323-339) is often synthesized at high purity (typically >95%) This sequence is OVA (ovalbumin) peptide residues 257 to 280, also known as OT-II (OVA-specific T-cell receptor) peptide, the core H2b-restricted class II to ensure that experimental outcomes are not skewed by contaminants.
The OT-II Connection
The term OT-II refers to a specific transgenic mouse model (classically identified as 004194 B6.Cg- OVA Peptide (323-339), ovalbumin ; Molecular Weight. 1772.9 ; Formula. C74H121N27O24 ; Sequence. Ile-Ser-Gln-Ala-Val-His-Ala-Ala-His-Ala-Glu-Ile-Asn-Glu-Ala-Gly- Tg(TcraTcrb)425Cbn/J). These models are engineered to express T-cell receptors that specifically recognize the aforementioned ovalbumin residues. By utilizing this model, researchers can observe how these biological systems respond to the introduction of the OTII epitope.
It is important to differentiate this from other common sequences, such as the OVA (ovalbumin) peptide residues 257 to 280 or the shorter Sequence: SIINFEKL (which corresponds to the OVA peptide 257-264). While the latter is a class I-restricted epitope, the OTII research focus remains heavily anchored on the longer 323-339 region presented by MHC class II molecules.
Comparative Analysis and Variations
Beyond the primary 323-339 segment, researchers often explore other regions of the ovalbumin protein. Documents frequently reference aa 243-248, aa 127-136 as additional epitope regions of interest. These variations allow for a granular understanding of how different structural motifs interact within a binding groov In vivo assembly of epitope-coated biopolymer particles e.
Whether one is working with the full OVA Peptide (323-339), ovalbumin construct or examining the nuance of a truncated sequence, the consistency of the peptide sequence is paramount. My experience suggests that paying c OVA Peptide (323-339), ovalbumin lose attention to the solubility and purity of these synthetic products is the most effective way to ensure reproducible result OT-II mice s.
Observations for Researchers
In my review of laboratory practices, the following points are critical for anyone engaging with this material:
1. Purity Matters: Always verify the cert DO11.10 and OT-II T cells recognize a C-terminal ovalbumin ificate of analysis for your OVA 323-339 peptide. Impurities can lead to non-specific binding, which complicates data interpretation.
2. Structural Context: Remember that the OT-II model is highly specific to the 323-339 residue range. Substituting this with other sequences—like the Sequence: SIINFEKL—will not yield the desired interaction within these transgenic models.
3. Documentation: Keep detailed logs of the peptide batch numbers and their specific sequences. Given the overlap in nomenclature (e.g., distinguishing between 323-339 and 257-280), clear labeling prevents costly experimental errors.
B This reagent recognizes a register of the ova 323-339 peptide that is present in wild-type CD4 T cell responses, but it does not bind to OT-II TCR transgenic T y focusing on these verifiable details and maintaining rigorous standards in handling, the study of these specific protein fragments continues to provide invaluable insights into molecular recognition and biological specificity.